日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective Study

肝硬化患者实验室指标与隐匿性肝性脑病的相关性:一项多中心回顾性研究

Koyano, Kaori; Atsukawa, Masanori; Tsubota, Akihito; Kondo, Chisa; Miwa, Takao; Namisaki, Tadashi; Hiraoka, Atsushi; Toyoda, Hidenori; Tada, Toshifumi; Kobayashi, Yuji; Kawata, Kazuhito; Matsuura, Kentaro; Mikami, Shigeru; Kawabe, Naoto; Oikawa, Tsunekazu; Suzuki, Kenta; Kawano, Tadamichi; Okubo, Tomomi; Arai, Taeang; Tani, Joji; Morishita, Asahiro; Iwasa, Motoh; Ishikawa, Toru; Ikegami, Tadashi; Tanaka, Yasuhito; Shimizu, Masahito; Yoshiji, Hitoshi; Iwakiri, Katsuhiko

Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C

Mac-2结合蛋白聚糖异构体可预测慢性丙型肝炎持续病毒学应答后所有恶性肿瘤的发生。

Kawata, Kazuhito; Atsukawa, Masanori; Ohta, Kazuyoshi; Chida, Takeshi; Noritake, Hidenao; Arai, Taeang; Iwakiri, Katsuhiko; Yasuda, Satoshi; Toyoda, Hidenori; Okubo, Tomomi; Hiraoka, Atsushi; Watanabe, Tsunamasa; Uojima, Haruki; Nozaki, Akito; Tani, Joji; Morishita, Asahiro; Kageyama, Fujito; Sasada, Yuzo; Nagasawa, Masamichi; Matsushita, Masahiro; Oyaizu, Tatsuki; Mikami, Shigeru; Ikegami, Tadashi; Abe, Hiroshi; Matsuura, Kentaro; Tanaka, Yasuhito; Tsubota, Akihito

Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus

SGLT2抑制剂对合并糖尿病的非酒精性脂肪性肝病患者的抗纤维化作用及长期疗效

Arai, Taeang; Atsukawa, Masanori; Tsubota, Akihito; Mikami, Shigeru; Haruki, Uojima; Yoshikata, Keiichiro; Ono, Hiroki; Kawano, Tadamichi; Yoshida, Yuji; Tanabe, Tomohide; Okubo, Tomomi; Hayama, Korenobu; Nakagawa-Iwashita, Ai; Itokawa, Norio; Kondo, Chisa; Kaneko, Keiko; Nagao, Mototsugu; Inagaki, Kyoko; Fukuda, Izumi; Sugihara, Hitoshi; Iwakiri, Katsuhiko

The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C

肝硬化和肝细胞癌病史对慢性丙型肝炎患者根除丙型肝炎病毒后全因死亡率的影响

Toyoda, Hidenori; Atsukawa, Masanori; Uojima, Haruki; Nozaki, Akito; Takaguchi, Koichi; Hiraoka, Atsushi; Itobayashi, Ei; Watanabe, Tsunamasa; Matsuura, Kentaro; Shimada, Noritomo; Abe, Hiroshi; Tsuji, Kunihiko; Itokawa, Norio; Mikami, Shigeru; Ishikawa, Toru; Oikawa, Tsunekazu; Yasuda, Satoshi; Chuma, Makoto; Tsutsui, Akemi; Ikeda, Hiroki; Arai, Taeang; Tsubota, Akihito; Kumada, Takashi; Tanaka, Yasuhito; Tanaka, Junko

Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study

雷迪帕韦和索非布韦治疗慢性丙型肝炎病毒2型基因感染患者的真实世界病毒学疗效和安全性:一项多中心研究

Tada, Toshifumi; Kumada, Takashi; Okushin, Hiroaki; Tani, Joji; Takaguchi, Koichi; Tsutsui, Akemi; Toyoda, Hidenori; Yasuda, Satoshi; Dohmen, Kazufumi; Hiraoka, Atsushi; Michitaka, Kojiro; Nouso, Kazuhiro; Kariyama, Kazuya; Kim, Soo Ryang; Kim, Soo Ki; Fujioka, Shinichi; Mikami, Shigeru; Watanabe, Yuto; Tamai, Tsutomu; Atsukawa, Masanori; Itokawa, Norio; Tanaka, Hironori; Tsuji, Kunihiko; Ishikawa, Toru; Imai, Michitaka; Itobayashi, Ei; Shibata, Hiroshi; Shimada, Noritomo

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data

钠-葡萄糖协同转运蛋白2抑制剂对非酒精性脂肪性肝病合并2型糖尿病患者的影响:基于真实世界数据的倾向评分匹配分析

Arai, Taeang; Atsukawa, Masanori; Tsubota, Akihito; Mikami, Shigeru; Ono, Hiroki; Kawano, Tadamichi; Yoshida, Yuji; Tanabe, Tomohide; Okubo, Tomomi; Hayama, Korenobu; Nakagawa-Iwashita, Ai; Itokawa, Norio; Kondo, Chisa; Kaneko, Keiko; Emoto, Naoya; Nagao, Mototsugu; Inagaki, Kyoko; Fukuda, Izumi; Sugihara, Hitoshi; Iwakiri, Katsuhiko

Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response

持续病毒学应答后新发肝细胞癌的特征和预后

Toyoda, Hidenori; Hiraoka, Atsushi; Uojima, Haruki; Nozaki, Akito; Shimada, Noritomo; Takaguchi, Koichi; Abe, Hiroshi; Atsukawa, Masanori; Matsuura, Kentaro; Ishikawa, Toru; Mikami, Shigeru; Watanabe, Tsunamasa; Itobayashi, Ei; Tsuji, Kunihiko; Arai, Taeang; Yasuda, Satoshi; Chuma, Makoto; Senoh, Tomonori; Tsutsui, Akemi; Okubo, Tomomi; Ehira, Takuya; Kumada, Takashi; Tanaka, Junko

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

对于慢性乙型肝炎患者,恩替卡韦序贯替诺福韦艾拉酚胺治疗与恩替卡韦单药持续治疗的比较

Itokawa, Norio; Atsukawa, Masanori; Tsubota, Akihito; Takaguchi, Koichi; Nakamuta, Makoto; Hiraoka, Atsushi; Kato, Keizo; Abe, Hiroshi; Mikami, Shigeru; Shimada, Noritomo; Chuma, Makoto; Akito, Nozaki; Uojima, Haruki; Ogawa, Chikara; Asano, Toru; Tani, Joji; Morishita, Asahiro; Senoh, Tomonori; Yamashita, Naoki; Oikawa, Tsunekazu; Matsumoto, Yoshihiro; Koeda, Mai; Yoshida, Yuji; Tanabe, Tomohide; Okubo, Tomomi; Arai, Taeang; Hayama, Korenobu; Iwashita, Ai-Nakagawa; Kondo, Chisa; Tada, Toshifumi; Toyoda, Hidenori; Kumada, Takashi; Iwakiri, Katsuhiko

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.

12 周索非布韦/维帕他韦治疗失代偿期肝硬化基因 1 型和 2 型患者的真实世界临床应用:一项前瞻性多中心研究

Atsukawa Masanori, Tsubota Akihito, Kondo Chisa, Toyoda Hidenori, Nakamuta Makoto, Takaguchi Koichi, Watanabe Tsunamasa, Hiraoka Atsushi, Uojima Haruki, Ishikawa Toru, Iwasa Motoh, Tada Toshifumi, Nozaki Akito, Chuma Makoto, Fukunishi Shinya, Asai Akira, Asano Toru, Ogawa Chikara, Abe Hiroshi, Hotta Naoki, Shima Toshihide, Iio Etsuko, Mikami Shigeru, Tachi Yoshihiko, Fujioka Shinichi, Okubo Hironao, Shimada Noritomo, Tani Joji, Hidaka Isao, Moriya Akio, Tsuji Kunihiko, Akahane Takehiro, Yamashita Naoki, Okubo Tomomi, Arai Taeang, Morita Kiyoshi, Kawata Kazuhito, Tanaka Yasuhito, Okanoue Takeshi, Maeda Shin, Kumada Takashi, Iwakiri Katsuhiko

Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan

日本高发老年患者、肝硬化和肝细胞癌地区无干扰素抗丙型肝炎病毒疗法的趋势和疗效:一项纳入10688例患者的真实世界、全国性、多中心研究

Toyoda, Hidenori; Atsukawa, Masanori; Uojima, Haruki; Nozaki, Akito; Tamai, Hideyuki; Takaguchi, Koichi; Fujioka, Shinichi; Nakamuta, Makoto; Tada, Toshifumi; Yasuda, Satoshi; Chuma, Makoto; Senoh, Tomonori; Tsutsui, Akemi; Yamashita, Naoki; Hiraoka, Atsushi; Michitaka, Kojiro; Shima, Toshihide; Akahane, Takehiro; Itobayashi, Ei; Watanabe, Tsunamasa; Ikeda, Hiroki; Iio, Etsuko; Fukunishi, Shinya; Asano, Toru; Tachi, Yoshihiko; Ikegami, Tadashi; Tsuji, Kunihiko; Abe, Hiroshi; Kato, Keizo; Mikami, Shigeru; Okubo, Hironao; Shimada, Noritomo; Ishikawa, Toru; Matsumoto, Yoshihiro; Itokawa, Norio; Arai, Taeang; Tsubota, Akihito; Iwakiri, Katsuhiko; Tanaka, Yasuhito; Kumada, Takashi